iNova Pharmaceuticals appoints Mr Will Delaat as a Director.
10 September 2010
iNova Pharmaceuticals today announced the appointment of Mr Will Delaat as a non-executive Director effective 17 August 2010.
Mr Delaat is currently the Independent Chairman of Medicines Australia (the industry group which represents the research-based prescription companies in Australia) and has close to 40 years experience in the Pharmaceutical Industry, including the Managing Director of Merck Sharp & Dohme Australia/NZ. He also holds a Non-Executive Directorship with Pharmaxis Pty Ltd, and is the Chairman of the Pharmaceuticals Industry Council.”
Paul Evans, Chairman of iNova said that Will had a key role to play on the iNova Board.
"Will brings with him extensive experience in growing successful pharmaceutical companies and his insight into the trends and future outlook of the industry makes him a very valuable addition to our Board. Over the past three years iNova has grown into a very significant Australian pharmaceutical company which can now benefit from Will’s contribution as we move to our next phase of growth.”
Mr Delaat started his pharmaceutical career in the UK, however the majority of his time has been spent in the Australian market, specialising in sales and marketing roles.
Upon his appointment Mr Delaat stated “I am passionate about the Australian pharmaceutical industry so I am very pleased to accept this appointment to the iNova Board and provide my experience to this exciting and growing Australian company.”